Navin Fluorine to interact with Analysts on Aug 20, 2026
Navin Fluorine will meet with analysts on August 20, 2026. The company reported Q1 FY27 consolidated revenue of ₹1,045 crore, up 44% YoY. EBITDA increased 73% to ₹357 crore. Specialty Chemicals revenue grew 48% and CDMO 82%. Capex includes ₹125 crore for cGMP4 Phase II by Q4 FY27.
The interaction with analysts and strong financial performance, coupled with significant capex plans for future growth, are material events for investors.
The company is actively engaging with investors and has reported strong financial results with significant year-on-year growth across key segments. Additionally, strategic capex plans indicate future growth.
Navin Fluorine International Limited will be interacting with Analysts in a group meeting on August 20, 2026, at 10:00 AM (IST). The company will present publicly available information during this meeting. Changes may occur due to exigencies on the part of the host or the company. The presentation to be made at the meetings is enclosed with this intimation and is also available on the company's website.
The company also reported its Q1 FY27 results, with Net Revenue from Operations at ₹1,045.08 crore, a 44% year-on-year increase. Operating EBITDA grew by 73% YoY to ₹357.07 crore, and Operating PBT rose by 101% YoY to ₹283.27 crore. The EBITDA margin stood at 34.2%, an increase of 566 basis points YoY. The Specialty Chemicals segment saw revenue growth of 48% YoY to ₹325 crore, and the CDMO business grew by 82% YoY to ₹180 crore. The High Performance Products (HPP) segment grew by 33% YoY to ₹407 crore. Several capex initiatives are underway, including additional HFC capacity, de-bottlenecking of MPP capacity, and Phase II of cGMP4 capex, with various completion timelines extending up to Q4 FY27. The company is also incubating an advanced materials vertical with a capex of ₹90 crore, expected to be completed by Q2 FY28.
What to do with a filing like this
Navin Fluorine International Limited filed this with the NSE as a statutory disclosure, categorised under investor meet intimation. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Navin Fluorine International Limited. Read the original for the full detail.